166 related articles for article (PubMed ID: 9714526)
1. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma.
Abildgaard N; Rungby J; Glerup H; Brixen K; Kassem M; Brincker H; Heickendorff L; Eriksen EF; Nielsen JL
Eur J Haematol; 1998 Aug; 61(2):128-34. PubMed ID: 9714526
[TBL] [Abstract][Full Text] [Related]
2. Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment.
Terpos E; Palermos J; Viniou N; Vaiopoulos G; Meletis J; Yataganas X
Calcif Tissue Int; 2001 May; 68(5):285-90. PubMed ID: 11683535
[TBL] [Abstract][Full Text] [Related]
3. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma.
Abildgaard N; Glerup H; Rungby J; Bendix-Hansen K; Kassem M; Brixen K; Heickendorff L; Nielsen JL; Eriksen EF
Eur J Haematol; 2000 Feb; 64(2):121-9. PubMed ID: 10997332
[TBL] [Abstract][Full Text] [Related]
4. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
Terpos E; Viniou N; de la Fuente J; Meletis J; Voskaridou E; Karkantaris C; Vaiopoulos G; Palermos J; Yataganas X; Goldman JM; Rahemtulla A
Eur J Haematol; 2003 Jan; 70(1):34-42. PubMed ID: 12631257
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
6. Short-term effects of pamidronate on biochemical markers of bone metabolism in osteoporosis--a placebo-controlled dose-finding study.
Mallmin H; Ljunghall S; Larsson K; Lindh E
Ups J Med Sci; 1991; 96(3):205-12. PubMed ID: 1810080
[TBL] [Abstract][Full Text] [Related]
7. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma.
Terpos E; Palermos J; Tsionos K; Anargyrou K; Viniou N; Papassavas P; Meletis J; Yataganas X
Eur J Haematol; 2000 Nov; 65(5):331-6. PubMed ID: 11092464
[TBL] [Abstract][Full Text] [Related]
8. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates and breast carcinoma.
Lipton A
Cancer; 1997 Oct; 80(8 Suppl):1668-73. PubMed ID: 9362434
[TBL] [Abstract][Full Text] [Related]
11. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
Body JJ; Facon T; Coleman RE; Lipton A; Geurs F; Fan M; Holloway D; Peterson MC; Bekker PJ
Clin Cancer Res; 2006 Feb; 12(4):1221-8. PubMed ID: 16489077
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of multiple myeloma patients by simultaneously measuring marker substances of bone resorption and formation.
Withold W; Arning M; Schwarz M; Wolf HH; Schneider W
Clin Chim Acta; 1998 Jan; 269(1):21-30. PubMed ID: 9498101
[TBL] [Abstract][Full Text] [Related]
13. New advances in the biology and treatment of myeloma bone disease.
Berenson JR
Semin Hematol; 2001 Apr; 38(2 Suppl 3):15-20. PubMed ID: 11309704
[TBL] [Abstract][Full Text] [Related]
14. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
Chapurlat RD; Hugueny P; Delmas PD; Meunier PJ
Bone; 2004 Jul; 35(1):235-42. PubMed ID: 15207763
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Berenson JR; Lichtenstein A; Porter L; Dimopoulos MA; Bordoni R; George S; Lipton A; Keller A; Ballester O; Kovacs MJ; Blacklock HA; Bell R; Simeone J; Reitsma DJ; Heffernan M; Seaman J; Knight RD
N Engl J Med; 1996 Feb; 334(8):488-93. PubMed ID: 8559201
[TBL] [Abstract][Full Text] [Related]
16. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates in multiple myeloma.
Berenson JR
Cancer; 1997 Oct; 80(8 Suppl):1661-7. PubMed ID: 9362433
[TBL] [Abstract][Full Text] [Related]
18. Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect.
Martín A; García-Sanz R; Hernández J; Bladé J; Suquía B; Fernández-Calvo J; González M; Mateo G; Orfao A; San Miguel JF
Br J Haematol; 2002 Jul; 118(1):239-42. PubMed ID: 12100153
[TBL] [Abstract][Full Text] [Related]
19. Pamidronate prevents bone loss associated with carrageenan arthritis by reducing resorptive activity but not recruitment of osteoclasts.
Moran EL; Fornasier TL; Bogoch TR
J Orthop Res; 2000 Nov; 18(6):873-81. PubMed ID: 11192246
[TBL] [Abstract][Full Text] [Related]
20. Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis.
Bravenboer N; Papapoulos SE; Holzmann P; Hamdy NA; Netelenbos JC; Lips P
Osteoporos Int; 1999; 9(6):489-93. PubMed ID: 10624455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
